

6
Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 58343

Manuscript Type: CASE REPORT

Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report

Komeda Y *et al.* Tofacitinib for UC and ITP

Yoriaki Komeda, Toshiharu Sakurai, Kazuko Sakai, Yasuyoshi Morita, Arito Hashimoto, Tomoyuki Nagai, Satoru Hagiwara, Itaru Matsumura, Kazuto Nishio, Masatoshi Kudo

Abstract

Match Overview

1	Crossref 28 words Valerio Papa, Maria Cristina Giustiniani, Loris Riccardo Lopetuso, Alfredo Papa. "Human herpesvirus 8-associated colo	2%
2	Internet 26 words crawled on 06-Oct-2020 www.frontiersin.org	2%
3	Internet 24 words crawled on 04-Jan-2020 bmcbgenomics.biomedcentral.com	2%
4	Internet 23 words www.ncbi.nlm.nih.gov	2%
5	Crossref 22 words Jeffrey S Hyams, Sonia Davis Thomas, Nathan Gotman, Ya el Haberman et al. "Clinical and biological predictors of res ...	2%
6	Internet 15 words crawled on 20-Jun-2019 f6publishing.blob.core.windows.net	1%



ALL

IMAGES

VIDEOS

6,430 Results

Any time ▼

Ulcerative colitis - ncbi.nlm.nih.gov

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487890>

Apr 29, 2017 · Introduction. **Ulcerative colitis** is a chronic, **idiopathic** inflammatory disease that affects the colon, most commonly affiicting adults aged 30–40 years and resulting in disability. 1,2 It is characterised by relapsing and remitting mucosal inflammation, starting in the rectum and extending to proximal segments of the colon. The aim of therapy is to induce and maintain ...

Medical Therapy of Active Ulcerative Colitis

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608602>

Introduction. Although the etiopathogenesis **of ulcerative colitis** (UC) remains elusive, substantial progress in the understanding of the development and progression of UC as well as the establishment of effective treatment strategies has been achieved in the past decades (fig. (fig.1). 1).The clinical course of UC is highly variable and ranges from a single episode to potentially life ...

Cited by: 1

Author: Martin Bürger, Carsten Schmidt, Niels T...

Publish Year: 2015

Thrombocytopenia and Idiopathic Thrombocytopenic Purpura

<https://www.webmd.com/a-to-z-guides/thrombocytopenia-symptoms-causes-treatments> ▼

A newer drug called fostamatinib (Tavalisse), a spleen tyrosine kinase **inhibitor**, is designed to treat thrombocytopenia in adults with chronic ITP who haven't gotten better with other treatments ...

Tofacitinib Treatment of Refractory Systemic Juvenile ...

<https://pediatrics.aappublications.org/content/143/5/e20182845> ▼

May 01, 2019 · Systemic juvenile **idiopathic** arthritis (sJIA) is an aggressive form of childhood arthritis accompanied by persistent systemic inflammation. Patients with sJIA often exhibit poor response to conventional disease-modifying antirheumatic drugs, and chronic glucocorticoid use is associated with significant adverse effects. Although biologics used to target interleukin 1 and ...

Cited by: 8

Author: Zhixiang Huang, Pui Y. Lee, Xiaovan Ya...

Refractory case of ulcerative colitis with idiopathic thrombocytopen



ALL

IMAGES

VIDEOS

12,900 Results

Any time ▼

Successful management with Janus kinase inhibitor ...

<https://academic.oup.com/rheumatology/advance...> ▼

AbstractObjectives. JDM is a rare autoimmune inflammatory muscle disease with a pronounced IFN signature. Treatment for children with JDM has improved over the

New therapeutic perspectives to manage refractory immune ...

<https://www.thelancet.com/journals/lanonc/article/...>

Immune checkpoint inhibitors are reshaping the prognosis of many cancer and are progressively becoming the standard of care in the treatment of many tumour types. Immunotherapy is bringing new hope to patients, but also a whole new spectrum of toxicities for healthcare practitioners to manage. Oncologists and specialists involved in the pluridisciplinary management of patients with cancer are ...

Cited by: 69

Author: Filipe Martins, Gerasimos P Sykiotis, Miche...

Publish Year: 2019

Tofacitinib Treatment of Refractory Systemic Juvenile ...

<https://pediatrics.aappublications.org/content/143/5/e20182845> ▼

May 01, 2019 · Authors of a **case report** described **successful** treatment of polyarticular JIA and collagenous **colitis** by using **tofacitinib** in a 58 year-old female patient diagnosed with JIA at age 10 years. 19 Results from a phase I trial in children with polyarticular JIA revealed no adverse effects associated with short-term administration of **tofacitinib**. 8 A ...

ALL

IMAGES

VIDEOS

13,000 Results

Any time ▼

Successful management with Janus kinase inhibitor ...

<https://academic.oup.com/rheumatology/advance...> ▼

AbstractObjectives. JDM is a rare autoimmune inflammatory muscle disease with a pronounced IFN signature. Treatment for children with JDM has improved over the

New therapeutic perspectives to manage refractory immune ...

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(18\)30828-3/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30828-3/fulltext)

Immune checkpoint inhibitors are reshaping the prognosis of many cancer and are progressively becoming the standard of care in the treatment of many tumour types. Immunotherapy is bringing new hope to patients, but also a whole new spectrum of toxicities for healthcare practitioners to manage. Oncologists and specialists involved in the pluridisciplinary management of patients with cancer are ...

Cited by: 69

Author: Filipe Martins, Gerasimos P Sykiotis, Mic...

Publish Year: 2019

Tofacitinib Treatment of Refractory Systemic Juvenile ...

<https://pediatrics.aappublications.org/content/143/5/e20182845> ▼

May 01, 2019 - Authors of a **case report** described **successful** treatment of polyarticular JIA and collagenous **colitis** by using **tofacitinib** in a 58 year-old female patient diagnosed with JIA at age 10 years. 19 Results from a phase I trial in children with polyarticular JIA revealed no adverse effects associated with short-term administration of **tofacitinib**. 8 A ...

Cited by: 9

Author: Zhixiang Huang, Pui Y. Lee, Xiaoyan Yao...

Publish Year: 2019

First two patients with ulcerative colitis who developed ...

<https://www.researchgate.net/publication/10980932...>

Request PDF | First two patients with **ulcerative colitis** who developed classical thrombotic **thrombocytopenic purpura successfully treated** with medical therapy and plasma exchange | ...

F Mana's research works | Clinique Saint-Jean Bruxelles ...

<https://www.researchgate.net/scientific-contributions/38267648-F-Mana>

Background **Tofacitinib**, an oral small molecule **Janus kinase inhibitor**, has been approved in 2018 for